Two part (double-blind inclisiran versus placebo [Year 1]followed by open-label inclisiran [Year 2]) randomizedmulticenter study to evaluate safety, tolerability, andefficacy of inclisiran in adolescents (12 to less than 18years) with heterozygous familial hypercholesterolemiaand elevated LDL-cholesterol (ORION-16)